IDH2型
血管免疫母细胞性T细胞淋巴瘤
癌症研究
生发中心
生物
肿瘤微环境
表观遗传学
等离子体电池
癌变
突变
B细胞
T细胞
免疫学
癌症
遗传学
基因
IDH1
抗体
免疫系统
肿瘤细胞
作者
Julie Leca,François Lemonnier,Cem Meydan,Jonathan Foox,Samah El Ghamrasni,Diana-Laure Mboumba,Gordon S. Duncan,Jérôme Fortin,Takashi Sakamoto,Chantal Tobin,Kelsey Hodgson,Jillian Haight,Logan K. Smith,Andrew Elia,Daniel Butler,Thorsten Berger,Laurence de Leval,Christopher E. Mason,Ari Melnick,Philippe Gaulard,Tak W. Mak
出处
期刊:Cancer Cell
[Elsevier]
日期:2023-02-01
卷期号:41 (2): 323-339.e10
被引量:26
标识
DOI:10.1016/j.ccell.2023.01.003
摘要
Angioimmunoblastic T cell lymphoma (AITL) is a peripheral T cell lymphoma that originates from T follicular helper (Tfh) cells and exhibits a prominent tumor microenvironment (TME). IDH2 and TET2 mutations co-occur frequently in AITL, but their contribution to tumorigenesis is poorly understood. We developed an AITL mouse model that is driven by Idh2 and Tet2 mutations. Malignant Tfh cells display aberrant transcriptomic and epigenetic programs that impair TCR signaling. Neoplastic Tfh cells bearing combined Idh2 and Tet2 mutations show altered cross-talk with germinal center B cells that promotes B cell clonal expansion while decreasing Fas-FasL interaction and reducing B cell apoptosis. The plasma cell count and angiogenesis are also increased in the Idh2-mutated tumors, implying a major relationship between Idh2 mutation and the characteristic AITL TME. Our mouse model recapitulates several features of human IDH2-mutated AITL and provides a rationale for exploring therapeutic targeting of Tfh-TME cross-talk for AITL patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI